Science-led biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Ultomiris, a long-acting C5 complement inhibitor, has gained FDA approval for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), offering relapse-free potential.
The CHAMPION-NMOSD Phase III trial demonstrates significant relapse risk reduction.
NMOSD, a rare autoimmune disease affecting the central nervous system, sees a diagnosed prevalence of around 6,000 adults in the US. Ultomiris's safety profile remains consistent, with no new adverse events observed.
Ultomiris, already approved in Japan and the EU for NMOSD, inhibits the complement cascade to prevent attacks on healthy cells.
AstraZeneca's rare disease-focused Alexion group leads the development of Ultomiris, aiming to serve patients with rare and devastating conditions globally.
Pfizer's Hympavzi (marstacimab-hncq) receives US FDA approval for Hemophilia A or B treatment
Capricor begins BLA submission for deramiocel in Duchenne muscular dystrophy
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Biogen receives FDA Breakthrough Therapy Designation for felzartamab
Inspira Technologies develops new disposable kit for perfusion market
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices